Investment Rating - The report maintains a rating of "Accumulate" for the company [6][10]. Core Views - The company's performance in the first half of 2025 shows stability, with revenue from pharmaceuticals and orthopedics leading the growth. The company continues to prioritize high dividend payouts, reflecting its commitment to shareholder returns [2][10]. Financial Summary - Total revenue for 2023 was 13,243.76 million RMB, with a projected increase to 13,889.42 million RMB in 2025, representing a growth of 6.1%. The net profit for 2023 was 2,001.91 million RMB, with a slight decrease expected to 2,033.02 million RMB in 2025, a decline of 1.6% [4][10]. - The company’s cash dividend ratio increased from 30% prior to 2023 to 40% in 2023, with a further increase to 50% expected by the end of 2024. The mid-year dividend for 2025 is also planned to be maintained at 50% [10]. Revenue Breakdown - The general medical device segment generated revenue of 33.0 billion RMB in the first half of 2025, remaining stable year-on-year. The pharmaceutical packaging segment also maintained revenue at 11.7 billion RMB, with significant growth in automatic injection pens, which saw a sales increase of approximately 200% [10]. - The orthopedics segment reported revenue of 7.3 billion RMB, a slight decrease of 1.6%, but with a substantial increase in segment profit by 74%. The interventional segment's revenue was 9.9 billion RMB, down by 2%, while the blood technology segment grew by 8.1% to 4.5 billion RMB [10]. Earnings Forecast - The report adjusts the earnings per share (EPS) forecast for 2025-2027 to 0.44, 0.50, and 0.56 RMB respectively, down from previous estimates of 0.51, 0.57, and 0.63 RMB [10]. - The target price for 2026 is set at 8.00 RMB, equivalent to 8.76 HKD, based on a target price-to-earnings (PE) ratio of 16X [10]. Market Data - The current stock price is 5.90 HKD, with a market capitalization of 26,967 million HKD and a 52-week price range of 4.15 to 7.22 HKD [7][10].

公司现金分红比例在2023年以前长期维持在30%，2023年全年分红比例提升至40%，2024年末期股息进 一步提升至全年50%。公司2025年中期分红拟维持50%的比例，彰显对股东回报的高度重视。 风险提示：新品放量不及预期，市场竞争加剧。 公司2025H1实现销售收入66.4亿元同比持平;经调整归母净利润(剔除汇兑损益影响)10.2亿元，同比下降 6.1%，主要系部分产品降价和新产品营销投入所致。 普耗趋稳，药包、骨科引领增长 公司2025H1通用医疗器械板块实现收入33.0亿元，同比基本持平，主要产品如输液器、留置针、注射器 等价格保持稳定，销量小幅增长;药包板块收入11.7亿元，同比基本持平，预灌封注射器国内销售单价稳 定，销量小幅增长，已与150余家新药企业开展合作，自动注射笔中国市场放量显著，2025H1销量增长 约200%，本土及海外市场均有较大潜力;骨科板块收入7.3亿元，同比略降1.6%，分部溢利同比大增 74%，其中脊柱同比环比均实现双位数增长，关节因销售模式变化表观承压，下半年有望加速放量;介 入板块收入9.9亿元，同比下降2%;血液技术板块收入4.5亿元，同比增长8.1%，其中拉德索斯 ...

Core Viewpoint - Cathay Securities maintains a "Buy" rating for Weigao Group (01066), adjusting the EPS forecast for 2025-2027 to 0.44/0.50/0.56 yuan from the previous 0.51/0.57/0.63 yuan, with a target price of 8.00 yuan (equivalent to 8.76 HKD) based on a target PE of 16X for 2026 [1] Group 1: Financial Performance - In H1 2025, the company achieved a sales revenue of 6.64 billion yuan, remaining flat year-on-year; adjusted net profit attributable to shareholders was 1.02 billion yuan, a decrease of 6.1% year-on-year, primarily due to price reductions on some products and increased marketing expenses for new products [2] Group 2: Business Segments Performance - The general medical device segment generated revenue of 3.30 billion yuan in H1 2025, remaining stable year-on-year, with key products like infusion sets and syringes maintaining stable prices and slight volume growth [3] - The pharmaceutical packaging segment reported revenue of 1.17 billion yuan, also flat year-on-year, with stable domestic sales prices for pre-filled syringes and significant volume growth of approximately 200% for automatic injection pens [3] - The orthopedic segment's revenue was 730 million yuan, a slight decline of 1.6% year-on-year, but segment profit increased by 74% year-on-year, with double-digit growth in spinal products [3] - The interventional segment's revenue was 990 million yuan, down 2% year-on-year, while the blood technology segment saw revenue of 450 million yuan, an increase of 8.1% year-on-year, with good recovery in overseas sales of the Radiosurgery device [3] Group 3: Shareholder Returns - The company has maintained a cash dividend ratio of 30% prior to 2023, increasing to 40% for the full year of 2023, and plans to further raise the dividend ratio to 50% by the end of 2024, with a proposed 50% dividend ratio for the mid-2025 period, highlighting a strong commitment to shareholder returns [4]

Summary of Key Points Core Viewpoint - On September 17, 28 Hong Kong-listed companies conducted share buybacks, totaling 16.7684 million shares and an aggregate amount of HKD 649 million [1][2]. Group 1: Share Buyback Details - Tencent Holdings repurchased 839,000 shares for HKD 551 million, with a highest price of HKD 663.50 and a lowest price of HKD 645.50, bringing its total buyback amount for the year to HKD 52.707 billion [1][2]. - Hang Seng Bank repurchased 200,000 shares for HKD 23.8014 million, with a highest price of HKD 119.30 and a lowest price of HKD 118.40, totaling HKD 793 million in buybacks for the year [1][2]. - Pacific Shipping repurchased 6 million shares for HKD 14.9526 million, with a highest price of HKD 2.52 and a lowest price of HKD 2.45, accumulating HKD 203 million in buybacks for the year [1][2]. Group 2: Ranking of Buybacks - The highest buyback amount on September 17 was from Tencent Holdings at HKD 551 million, followed by Hang Seng Bank at HKD 23.8014 million [1][2]. - In terms of share quantity, Pacific Shipping led with 6 million shares repurchased, followed by Linklogis Technology and Weigao Group with 2.3 million and 1.9548 million shares, respectively [1][2]. Group 3: Additional Buyback Information - Other notable companies involved in buybacks include Weigao Group, MGM China, and Jitu Express, with respective buyback amounts of HKD 11.4255 million, HKD 7.873 million, and HKD 7.8348 million [2][3]. - The buyback activity reflects a strategic move by these companies to enhance shareholder value amid market conditions [1][2].

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Hang Seng Bank, conducted share buybacks on September 17, 2025, with Tencent leading in both the number of shares repurchased and the total amount spent. Group 1: Company Buyback Details - Tencent Holdings (00700) repurchased 839,000 shares for a total of 551 million, with a year-to-date total of 58.158 million shares, representing 0.633% of its total share capital [1][2] - Hang Seng Bank (00011) repurchased 200,000 shares for 23.8014 million, with a year-to-date total of 6.93 million shares, representing 0.368% of its total share capital [2] - Pacific Shipping (02343) repurchased 6 million shares for 14.9526 million, with a year-to-date total of 41.006 million shares, representing 0.798% of its total share capital [2] - Weigao Group (01066) repurchased 1.9548 million shares for 11.4255 million, with a year-to-date total of 14.2136 million shares, representing 3.148% of its total share capital [2] - MGM China (02282) repurchased 502,000 shares for 7.873 million, with a year-to-date total of 2.23295 million shares, representing 0.587% of its total share capital [2] Group 2: Other Notable Buybacks - Jitu Express-W (01519) repurchased 870,000 shares for 7.8348 million, with a year-to-date total of 870,000 shares, representing 0.010% of its total share capital [2] - Linkage Technology-W (09959) repurchased 2.3 million shares for 7.4586 million, with a year-to-date total of 19.9075 million shares, representing 0.932% of its total share capital [2] - Mengniu Dairy (02319) repurchased 200,000 shares for 3.074 million, with a year-to-date total of 10.816 million shares, representing 0.276% of its total share capital [2] - China Hongqiao (01378) repurchased 112,500 shares for 2.822 million, with a year-to-date total of 150 million shares, representing 1.610% of its total share capital [2] - Coolpad Group (02369) repurchased 1.348 million shares for 1.8057 million, with a year-to-date total of 23.095 million shares, representing 5.639% of its total share capital [2]

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.09.17 | 195.48 | 5.900 | 5.820 | 1142.55 | | 2025.09.16 | 53.00 | 5.940 | 5.820 | 312.22 | | 2025.09.15 | 95.60 | 5.850 | 5.790 | 557.62 | | 2025.09.12 | 31.96 | 5.900 | 5.770 | 187.85 | | 2025.09.11 | 42.92 | 5.690 | 5.570 | 242.48 | | 2025.09.10 | 72.00 | 5.720 | 5.660 | 408.78 | | 2025.09.09 | 114.00 | 5.750 | 5.700 | 652.12 | | 2025.09.08 | 47.28 | 5.690 | 5.610 | 266.60 | | 2025.09.05 | 37.80 | 5.680 | 5.630 | ...

每经AI快讯，9月17日，威高股份(01066.HK)在港交所发布公告称，当日在香港斥资约1142.5万港元回 购股份195万股，每股回购价在5.82至5.9港元。 ...

威高股份(01066.HK)公告，9月17日耗资1142.5万港元回购195.5万股。 ...

威高股份(01066)发布公告，于2025年9月17日斥资1142.55万港元回购195.48万股。 ...

智通财经APP讯，威高股份(01066)发布公告，于2025年9月17日斥资1142.55万港元回购195.48万股。 ...